Importance of Fostering International Collaboration for Optimal Outcomes of Kawasaki Disease Worldwide
Updated: May 18, 2026
- Untreated Kawasaki disease (KD) patients can develop coronary artery aneurysms (CAAs) with a prevalence of ~25%, whereas prompt treatment with intravenous immunoglobulin (IVIG) (2g/kg/dose) can reduce the risk to <5%.
- KD management has succeeded in large experienced and economically advanced countries where research collaboration has been impactful.
- The collaboration is expected to benefit all consortia members proportionate to their contribution, especially for members from LMICs. The ultimate goal, however, remains patients’ outcomes under a globally harmonized approach for optimal care.